Thrilled to celebrate Parabilis Medicines’ record IPO today! A massive win for the team and validation of their lead therapeutic candidate zolucatetide. This will serve as a blueprint for the next generation of precision medicine.
Congratulations to the entire team at Parabilis Medicines on going public today.
Since our first investment in 2018, it has been an honor to support Greg, @mmammen, and team as they translate complex science into clinical results.
Krishna Yeshwant retweeted
To see how OpenEvidence is truly transforming healthcare, read our blog:
gv.com/news/openevidence-ai-…
Krishna Yeshwant retweeted
.@openevidence just closed their $210M Series B and we’re thrilled to co-lead the round alongside @kleinerperkins. OpenEvidence allows clinicians to get immediate evidence-based answers at the point of care and is used today by 40% of doctors in the US. Congrats to founder Daniel Nadler and the team!
Krishna Yeshwant retweeted
Lenny's Podcast is one of our favorites for actionable startup advice, so it was awesome to have GV's @mmargolis as a guest. Michael breaks down how to quickly zero in on your bullseye customer and value prop — in one day! Have a listen 🎧
Michael Margolis (@mmargolis) has been a UX research partner at @GVteam for nearly 15 years, and through his hands-on work with over 300 startups has developed a unique approach to helping founders identify their “bullseye customer”—the specific subset of their target market who initially is most likely to adopt their product.
In our conversation, Michael shares:
🔸 The step-by-step process of running a bullseye customer sprint
🔸 The most common mistakes founders make when picking their first customers
🔸 Practical tips for conducting effective customer interviews
🔸 The power of “watch parties” in aligning teams around customer insights
🔸 How to apply these methods beyond typical tech startups
🔸 Much more
Listen now 👇
- YouTube: youtu.be/B6Dt1sgGmLI
- Spotify: open.spotify.com/episode/59x…
- Apple: podcasts.apple.com/us/podcas…
Thank you to our wonderful sponsors for supporting the podcast:
🏆 @Get_Eppo — Run reliable, impactful experiments: geteppo.com/
🏆 @useparagon — Ship every SaaS integration your customers want: useparagon.com/lenny
🏆 @enterpret_ai — Transform customer feedback into product growth: enterpret.com/lenny
Krishna Yeshwant retweeted
Counterfeiting costs retailers billions every year 💸Osmo’s AI-powered sensors are transforming authentication by detecting real products from fake ones with precision. Be part of the future—join the Osmo community today: osmo.ai/community #DigitalOlfaction #Osmo #ScentTech
Krishna Yeshwant retweeted
Well, we actually did it. We digitized scent. A fresh summer plum was the first fruit and scent to be fully digitized and reprinted with no human intervention. It smells great.
Holy moly, I’m still processing the magnitude of what we’ve done. And yet, it feels like as we cross this finish line we are instantly at a new starting line. I’ll have more to share about what’s in store that we’re building on top of this.
A huge HUGE congrats to the entire team across scientific, engineering, operational, and creative disciplines. It takes a village named Osmo to do this.
I don’t know if this is embarrassing, but I carry the plum scent with me a lot of places and smell it constantly. It makes me smile.
I’m curious, if y’all want to smell it? If we made a limited release fragrance of the first teleported scent and dedicated the proceeds to science, would you want it?
Krishna Yeshwant retweeted
“Venture at its best is able to support founders in making the impossible possible...That ethos is something that’s in GV’s DNA.”
@FortuneMagazine’s @agarfinks looks inside the first 15 years of GV and our plans for the next 300 — fortune.com/2024/09/20/insid…
Krishna Yeshwant retweeted
Ive had the pleasure of spending time with @awiltschko including touring their NY 🗽 facility and labs.
What the @Osmo_Labs team is building is absolutely mind blowing and the use cases will be many! 🤯
Just as importantly; the culture in the office is awesome and testament to Alex and his teams leadership. SUPER excited about this one! @GVteam
“We will eventually be able to detect disease with scent, and we’re on our way to building that technology.”
By training AI models on olfactory data, @Osmo_Labs’ @awiltschko is transforming how humans approach consumer production, healthcare, and more — cnb.cx/3MgSiPE
Krishna Yeshwant retweeted
Congratulations to the 2024 ACS Division of Medicinal Chemistry #HOF Inductees! This years inductees have a long‐standing record of achievement in medicinal chemistry. We will honor inductees at a reception at the Fall ACS national meeting in Denver and we hope to see you there!
Krishna Yeshwant retweeted
Welcome to GV, Santa Ana Bio!
We're thrilled to lead Santa Ana Bio's Series B as the company furthers the development of targeted therapies for patients with autoimmune and inflammatory diseases.
Learn more about today's news in @FierceBiotech — fiercebiotech.com/biotech/in…
Welcome to the team, Elena! We’re excited to work with you. xitter.cf/GVteam/status/17925709…
We're excited to announce @elena_sakach as our newest investment partner in SF!
Elena will lead investments across fintech, software, and AI. We’re incredibly excited to see her impact at GV and across the portfolio. Welcome to the team! bit.ly/4bme0ws
Krishna Yeshwant retweeted
I’ve been doing 20VC for 10 years.
There have been good times, there have been bad times.
Through all of them, @Thulme has been there for me.
He is one of the greats, and this show was a result of years in friendship.
My top lessons 👇
Proud to get to work with @thulme - Great interview!
“At GV, anyone can bring forward an idea and explore it.”
GV’s @thulme sat down with @HarryStebbings' @twentyminutevc to talk about building great cultures, advice for founders, and insights from decades in venture — bit.ly/4box64A
Krishna Yeshwant retweeted
We are so excited to work with Kevin and his team on a completely novel approach to cancer therapy with the potential to help patients with cancer
“We’re flipping the script, doing the exact opposite of the past 30 years. That’s bold and grounded in bedrock data.”
Congrats to GV entrepreneur in residence @marksy11 on the launch of Delphia and pioneering activation lethality to improve cancer care — bit.ly/3xTOHTB
Krishna Yeshwant retweeted
Congratulations to GV EIR @marksy11 on the launch of Delphia Tx! 🎊@leilei_wuu talks with Kevin and @schenkein about flipping the script on cancer care w/ activation lethality: endpts.com/biotech-vets-rais…
Krishna Yeshwant retweeted
We're excited to announce @NicoleGaudelli as GV’s newest life sciences entrepreneur in residence! 🎉🧬
As an esteemed scientist and Adenine Base Editing inventor, Nicole will advance next-generation genomic medicines. Learn more in @Forbes ➡️ forbes.com/sites/katiejennin…
We’re incredibly excited to congratulate our longtime friend and colleague Anthony Philippakis as GV’s newest general partner. Congratulations! biopharmadive.com/news/gv-an…
Krishna Yeshwant retweeted
GV is excited to announce its newest investing partners: Karthik Ardhanareeswaran, @KJSidz, and Sherry Chao!
Based in our SF, NYC, and Cambridge offices, our new partners invest in life sciences and consumer startups. Congrats to Karthik, KJ, and Sherry on their promotions! 🎉
GV is thrilled to announce @mcbmichael as our newest general partner! 🎉
As the former CRO of portfolio company @gitlab with 30 years of go-to-market experience, Michael will invest in early-stage enterprise software companies — bit.ly/3RDyx8s
